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1. Introduction 
Anaemia, as a complication of end stage kidney disease (ESKD), is well studied (Eschbach 
and Adamson 1985). Reports indicate that anaemia in this patient population is associated 
with numerous morbidities, but predominantly cardiovascular complications such as left 
ventricular hypertrophy and heart failure (Wizemann, Schafer et al. 1993; Harnett, Foley et 
al. 1995). Contrary to the ample data available regarding anaemia in ESKD population, 
much less is known about the epidemiology of post-transplant anaemia (PTA), and only few 
studies have systematically investigated this issue (Saito, Fujiwara et al. 1998; Yorgin, 
Scandling et al. 2002; Mix, Kazmi et al. 2003; Vanrenterghem, Ponticelli et al. 2003).  
A successful renal allograft will correct not only the excretory functions of the kidney but 
also the endocrine functions (through the restored synthesis of erythropoietin and vitamin 
D) including the correction of anaemia. However, in the majority of transplant recipients, 
the renal graft does not function optimally. It is well known that renal excretory functions 
are not restored completely, but the extent to which renal endocrine functions are restored is 
only recently becoming better understood. A recent European survey of ten transplant 
centres revealed a prevalence of PTA as high as 42% (Molnar et al, 2011). 
PTA may occur at any time after renal transplantation. Early PTA (from the time of surgery 
until 3 months post-operatively) is most likely to be related to pre-transplant anaemia of 
ESKD, the surgery itself, iron deficiency, immunosuppression, inflammation or infection 
(Miles, Markell et al. 1997; Turkowski-Duhem, Kamar et al. 2005) or some combination of 
these. Later PTA is more likely to be related to consequences of long-term 
immunosuppression (particularly anti-metabolite medications) or a failing allograft. All the 
published large scale studies to date have focused mainly on late PTA (Miles, Markell et al. 
1997; Vanrenterghem, Ponticelli et al. 2003; Turkowski-Duhem, Kamar et al. 2005), and there 
are a lack of studies looking at the management of early PTA, in particular, the optimal 
management of iron deficiency at the time of kidney transplantation. 
The importance of PTA is that it is one of the commonest complications after kidney 
transplantation, that it is strongly associated with cardiovascular morbidity (the primary 
cause of death of kidney transplant recipients, accounting for approximately one half of 
such deaths), and that its optimal treatment, either with iron, erythropoietin, or other agents, 
has yet to be determined by large-scale randomised controlled trials. 
2. Prevalence 
PTA remains a common complication after kidney transplantation, with an incidence 
ranging from nearly 80% at day 0 to as low as 25% at 1 year (Saito, Fujiwara et al. 1998; 
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Yorgin, Scandling et al. 2002; Mix, Kazmi et al. 2003; Vanrenterghem, Ponticelli et al. 2003). 
To date, there are very few published studies of PTA, and very few presenting data on 
interventions for PTA.  
One of the largest studies (Vanrenterghem, Ponticelli et al. 2003) was published in the 
American Journal of Transplantation, and included 4,263 kidney transplant patients from 72 
centres in 16 European countries (TRansplant European Survey on Anaemia Management 
[TRESAM] survey). The patients were divided into four cohorts and assessed at 6 months 
(n=1003), 1 year (n=960), 3 years (n=1254) and 5 years (n=1046) after kidney transplantation. 
Recipients of multiple organs, pregnant women and children aged <10 years were excluded 
from the study.  
Demographic data indicate that the patients included in the TRESAM survey were 
representative of the European transplant population. Approximately 60% of patients were 
male and 40% were female, and these proportions were similar in the four cohorts. The 
mean (SD) age of transplant recipients at transplantation was 45.5 (13.1) years, although 
patients who had received their transplant more recently were significantly (p=0.01) older at 
transplantation than patients who had received their transplant 5 years ago. The proportion 
of patients in this survey who had received their kidney from a living donor was relatively 
low (~10%). The most prevalent underlying kidney disease in the TRESAM survey was 
chronic glomerulonephritis (29.8-37.0% across the four cohorts). The prevalence of diabetic 
nephropathy was uncharacteristically low (6.5-7.5%) by contemporary standards. The most 
frequently occurring co-morbidities were coronary artery disease (13.0-16.1%), hepatitis B/C 
(9.3-10.8%) and type 2 diabetes mellitus (8.7-10.1%). 
Pre-transplant haemoglobin (Hb) concentrations in one study were significantly higher in 
patients who had received their transplant more recently than in patients who had received 
their transplant 5 years earlier, suggesting progressive anaemia with time. In that study, the  
mean Hb concentrations were 11.9 g/dL in the 6 month cohort vs 10.8 g/dL in the 5 year 
cohort (p<0.01; Eschbach and Adamson, 1985) 
Anaemia, defined as Hb concentration < 13 g/dL for male patients and ≤ 12 g/dL for female 
patients, was present in 38.6% of patients overall in this survey, and was equally distributed 
between the sexes. Of these patients, 11.6% had moderate anaemia (Hb concentration >11 
and ≤ 12 g/dL for male patients and >10 and ≤11g/dL for female patients), while 8.5% had 
severe anaemia (Hb concentrations ≤11g/dL for male patients and ≤10 g/dL for female 
patients). In patients with a serum creatinine levels >2 mg/dL, 60.1% were considered 
anaemic, whereas in patients with a serum creatinine level ≤ 2 mg/dL, only 29.0% of 
patients were considered anaemic (p<0.01). The findings of the TRESAM survey were in 
agreement with the results published by a contemporary American group (Yorgin, 
Scandling et al. 2002).  The aforementioned 5-year follow up of the TRESAM survey (Molnar 
et al, 2011) reported similar rates of anaemia at 42% overall, suggesting that the problem is 
not improving over time despite awareness of the problem. 
The group from Boston, MA undertook a retrospective longitudinal cohort study (Mix, 
Kazmi et al. 2003) to characterise changes in haematocrit (Hct) following kidney 
transplantation and to identify factors associated with those changes. The study included 
240 patients who underwent kidney transplantation in Tufts-New England Medical Centre, 
Boston, MA. Hct levels were available for 94% of patients at 1-month follow-up and for 95-
100% of patients at subsequent follow-up intervals. At the time of transplant surgery, 22% 
(95% CI 16%, 28%) of the cohort had Hct < 30%. The mean Hct rose from its nadir of 33% 
(95% CI 27%. 39%), both at the time of transplantation and at 1 month after transplantation, 
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to a peak of 40% (95% CI 34%, 46%) 12 months after transplantation, and declined thereafter. 
During the first year after transplantation, the proportion of patients with Hct <36% steadily 
decreased from 76% (95% CI 70%, 82%) at transplantation to 21% (95% CI 15%, 27%) at 12 
months after transplantation. The proportion of patients with Hct < 33% declined over a 
shorter time interval, from 48% (95% CI 42%, 54%) at transplantation to 7% (95% CI 3%, 
11%) at 6 months after transplantation. These data closely reflect the European experience as 
previously described. 
3. Risk factors for PTA 
In the post-transplant setting anaemia may be contributed to by blood loss, iron deficiency, 
bone marrow suppression by anti-proliferative agents (mycophenolate, azathioprine), 
erythropoietin deficiency, and inflammation (Table 1). The relative contributions of these 
components may be difficult to ascertain in an individual patient and may often be due to a 
combination of these factors.  
 
Early PTA  Late PTA 
Immunosuppressive agents  ↓ red cell survival 
Surgical blood loss   Immunosuppressive agents 
Frequent blood sampling   ↓erythrocyte production  
Drugs-ACEi/ARB   Low excretory +/- endocrine graft function 
Iron deficiency    EPO resistance    
Delayed graft function 
Persistent uraemic toxins 
ACEi=Angiotensin converting enzyme inhibitor, ARB=Angiotensin Receptor Blocker.  
EPO resistance is defined as the need of ≥300IU/Kg/week. 
Table 1. Common risk factors for PTA 
3.1 Early PTA 
A prospective study (Turkowski-Duhem, Kamar et al. 2005) published in Transplantation 
attempted to identify independent predictors of  anaemia at 6 months and 12 months post-
transplant. The authors studied 99 patients who had undergone kidney transplantation at 
Toulouse University Hospital between January 2001 and January 2002. Anaemia as defined 
by WHO criteria was observed in 38.6% of patients, which is a very similar rate to that 
found in other published studies from the same era. 
Immunosuppressive treatment, particularly with antimetabolite drugs, is one of the most 
likely contributors to PTA. The purine synthesis inhibitors, azathioprine and mycophenolate 
mofetil (MMF), are known to cause anaemia (Gossmann, Kachel et al. 1993; de Sevaux, 
Hilbrands et al. 1998; Kuypers, Claes et al. 2004; Shipkova, Spielbauer et al. 2004). 
Macrocytosis was present in the majority of the patients in those studies treated with 
azathioprine. Mammalian target of rapamycin (mTOR) inhibitors (e.g., sirolimus) are also 
associated with PTA, and particularly with microcytosis even in the absence of iron 
deficiency (Thaunat, Beaumont et al. 2007). In that study nearly all patient received 
concomitant MMF and for the 42.3% who received induction therapy with rabbit 
antithymocyte globulin (ATG), the incidence of PTA was lower than previously reported 
values, at only 25% at 1 year post-transplantation. This could merely reflect selection bias.  
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Some recent report suggests that sirolimus-based therapy was an independent factor of PTA 
(Augustine, Knauss et al. 2004). For example, the prevalence of PTA was 31% with MMF-
based immunosuppression and as high as 57% with sirolimus-based immunosuppression. 
Through mTOR inhibition, sirolimus blocks S6 kinase activity and consequently impairs cell 
replication in an erythroid cell line (Jaster, Bittorf et al. 1996) leading to anaemia. 
One other obvious contributor to post-transplant anaemia is iron deficiency. Iron deficiency, 
defined by low ferritin and a low transferrin saturation, was present in 17% (Mahmud, Aziz 
et al. 2002) and 34.6%(Kim, Park et al. 2003) of anaemic patients in the post-transplant 
setting. Patients coming to kidney transplantation are known to be frequently iron deficient 
both in absolute and functional terms (Lorenz, Kletzmayr et al. 2002).  
Many studies have demonstrated that the occurrence of PTA is related to renal allograft 
function, with declining function related to worsening anaemia as is seen in the chronic 
kidney disease (CKD) population. The results of the TRESAM survey showed a strong 
correlation between Hb levels and graft function expressed as serum creatinine and 
creatinine clearance: the majority of anaemic patients had creatinine levels > 2 mg/dL 
(Vanrenterghem, Ponticelli et al. 2003). Turkowski-Duhem found an effect of post-transplant 
renal function on haemoglobin levels at 6 months. Both delayed graft function (DGF) and 
renal allograft function, defined by creatinine clearance, were independent factors 
associated with the occurrence of anaemia at 12 months post transplantation(Turkowski-
Duhem, Kamar et al. 2005). In another study  it was reported that at both 6 and 12 months 
post transplantation higher serum creatinine values (defined as each 1 mg/dL increase in 
serum creatinine level) were significant independent risk factors for anaemia (Shibagaki and 
Shetty 2004). Similarly, in a further study (Yorgin, Scandling et al. 2002) serum CO2, blood 
urea nitrogen (BUN) and creatinine correlated with anaemia at 1 year post transplantation 
(Yorgin, Scandling et al. 2002). These findings were explained by the decreased production 
of erythropoietin (Kuypers, Claes et al.)  and also the increase in erythropoietin (EPO) 
resistance relative to the decline in renal excretory function in the early 1990’s. (van 
Dullemen, Luykx-de Bakker et al. 1992).  
In the TRESAM survey, transplant recipients who had experienced one or more rejection 
episodes, or who had received a second or third graft, had lower haemoglobin levels than 
recipients without rejection episodes or recipients with a first transplant. An analysis using 
DNA microarrays identified a cluster of genes related to haemoglobin synthesis and/or 
erythropoiesis that was altered in kidneys with renal allograft rejection compared with 
normal allograft kidneys (Chua, Barry et al. 2003). 
Another factor relevant to early PTA is cytomegalovirus (CMV) infection. Turkowski-
Durhem showed on univariate analysis that at 12 months post transplantation, the 
prevalence of CMV seropositivity was significantly higher in those presenting with anaemia 
(78%) than in those without anaemia (51%), suggesting CMV infection might be a 
predisposing factor to PTA. However, on multivariate analysis, CMV status was no longer a 
significant predictor. . Mix et al. found that positive CMV donor status and negative 
recipient status (CMV D+/R-)  was a factor independently associated with a greater 
likelihood of PTA, in this case defined as a haematocrit (Hct) <36% at 6 months post 
transplantation (Mix, Kazmi et al. 2003). These two observations suggest that CMV infection 
itself, and/or the use of drugs to prevent or treat CMV infection/disease, might result in a 
degree of bone-marrow suppression leading to PTA. 
Angiotensin converting enzyme (ACE) inhibitor therapy is known to induce anaemia 
(Gossmann, Kachel et al. 1993), and has been used to treat post-transplant erythrocytosis 
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(Rostaing, Boisseau et al. 1995). The TRESAM survey reported that the use of ACE inhibitors 
or angiotensin II receptor blockers (ARB’s) was associated with a higher odds ratio for 
anaemia (OR=1.55); they also found that it increased the risk of severe anaemia. 
Winckelmayer et al. observed that patients taking ACE inhibitors had significantly lower 
Hct levels compared with patients not taking them.  In addition, a significant curvilinear 
dose-response relationship was found between ACE inhibitor dose and Hct level. 
Turkowski-Durhem also observed that the platelet count at day-7 post transplantation was 
an independent predictive factor for anaemia at both 6 months (OR 0.12 (0.03-0.48); P=0.002) 
and 12 months (OR 0.096 (0.01 -1.04); P=0.05), i.e. more anaemic patients had a significantly 
lower platelet count (<200X109/L) than non-anaemic patients (72% vs. 38% at 6 months, and 
65% vs. 45% at 12 months). The significance of the association with platelet counts at day-7 
post transplant, and the occurrence of PTA at 6 and 12 months, persists even after excluding 
patients that received induction therapy with ATG because the latter can result in 
thrombocytopenia. There was no explanation given for this observation, although it could 
just represent a different measure of overall bone marrow suppression 
The other causes of early PTA have been attributed to blood loss at the time of surgery, 
frequent blood sampling and the persistent effect of uraemic toxins. 
3.2 Late PTA 
PTA that occurs late after transplantation has been attributed to decreased red blood cell 
survival (Najean, Rain et al. 1997), erythrocyte hypoproduction due to iron deficiency 
(Teruel, Lamas et al. 1989; Beshara, Birgegard et al. 1997; Miles, Markell et al. 1997), low 
excretory graft function (Miles, Markell et al. 1997), and immunosuppressive agents 
(Solheim, Albrechtsen et al. 1987; Yoshimura, Oka et al. 1989; Creemers, van Boven et al. 
1993; Zazgornik 1997). 
A retrospective longitudinal analysis (Yorgin, Scandling et al. 2002) of adult renal transplant 
recipients was published in American Journal of Transplantation looking at the prevalence, 
severity and predictors of late PTA. The study population of adults (>18 years) transplanted 
during 1995 at Stanford University (n=88) and University of North Carolina (n=40) were 
selected. Post-transplant anaemia was a common problem which affected 30% of the study 
population at least once during the first 5 years after transplant. Recurrence of PTA was 
common (50%) and the prevalence and severity of anaemia increased with time after 
transplantation. 
Renal excretory function is strongly correlated with anaemia in adult renal transplant 
recipients. Yet the effect of renal excretory function on anaemia is not absolute, as a small 
proportion of anaemic patients have creatinine clearance values > 75 mL/min/1.73 m2 (i.e. 
normal), whereas conversely, some non-anaemic patients have creatinine clearance < 50 
mL/min 1.73 m2.(Yorgin, Scandling et al. 2002). A study by van Dullemen et al. demonstrated 
that EPO production decreases and EPO resistance increases proportionally to the decline in 
renal excretory function (van Dullemen, Luykx-de Bakker et al. 1992). Other factors not related 
to declining renal excretory function include  DGF, acute tubulointerstitial rejection (Besarab, 
Caro et al. 1987; Heidenreich, Tepel et al. 1995), chronic rejection (Heidenreich, Tepel et al. 
1995) and possibly long-term calcineurin inhibitor toxicity (Jensen, Hansen et al. 1994) may 
contribute to PTA by leading to  diminished EPO production. 
Since renal tubular injury may be attributable to DGF, allograft rejection and calcineurin 
inhibitor toxicity in renal transplant recipients, and that all of these complications are 
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frequent, another factor which has been evaluated as an important indicator of renal tubular 
function is serum total CO2. In one study, Anaemic patients had lower serum total CO2 
values (p=0.019 at 1 year post transplant and p<0.0001 at 5 years post transplant) (Yorgin, 
Scandling et al. 2002). The authors speculate that the presence of metabolic acidosis is a 
surrogate indicator of renal tubular injury, diminished renal excretory function and 
diminished EPO production, however this hypothesis has not been tested. 
Yorgin et al also found that few anaemic patients were ever treated with EPO or even iron 
therapy. This finding may demonstrate a need for increased awareness of anaemia and 
increased concern about subnormal Hct by the patient's primary nephrologists and 
transplant physicians. 
4. Treatment of PTA 
There is a paucity of good quality and large scale intervention trials for PTA in the 
transplant literature, although some registry studies and multi-centre surveys do shed some 
light on practice patterns. For example, in the TRESAM survey rates of ESA use were 
reported. Surprisingly, of the 3969 patients overall for whom the use of erythropoietic 
therapy was documented, only 207 (5.2%) had received an erythropoietin-stimulating agent 
(ESA) for the treatment of anaemia. Even more striking was the fact that among the group of 
anaemic patients (n=1539), only 10% had received an ESA or other specific therapy. Of the 
343 patients with severe anaemia, 17.8% were treated with erythropoietic therapy (Fig 1). 
 
  
Fig. 1. Epoetin treatment in the TRESAM survey. 
Possible reasons for the reluctance of nephrologists to correct anaemia in transplant patients 
include a relative paucity of published studies on intervention strategies for PTA, an under-
recognition of the importance of the problem in terms of contribution to overall 
cardiovascular risk (also due to lack of specific studies demonstrating this) and finally the 
“psychological factor” of concerns regarding the efficacy and safety of therapy. In terms of 
safety of therapy, there have been concerns regarding the normalisation of Hb 
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concentrations with ESA in the CKD population and. A few studies, involving small number 
of patients, have suggested that transplant recipients treated with epoetin develop 
hypertension, which requires treatment with anti-hypertensive drugs (Muirhead 1999; Kim, 
Park et al. 2003). However, to date, there have been no indications that patients treated with 
erythropoietic therapy after transplantation show a more rapid deterioration of their 
allograft function(Muirhead 1999).  
4.1 Erythropoietin-stimulating agent use 
Several small-scale studies suggest that ESA may be an effective treatment for post-
transplant anaemia (Traindl, Barnas et al. 1994; Muirhead 1999; Kim, Park et al. 2003). The 
study done by Lezaic (Lezaic, Djukanovic et al. 1995) suggested that the response to 
erythropoietic therapy of patients with anaemia post-transplant is comparable with that of 
anaemia due to other forms of renal failure. As EPO resistance is common in these patients, 
they should be evaluated for secondary or tertiary hyperparathyroidism, hypothyroidism, 
haemolysis, and GI blood loss if a reticulocyte spike is not detected 7 days post 
transplantation. 
Several recent studies in the CKD literature (Pfeffer et al. 2009, Drueke et al 2006) regarding 
haemoglobin targets have resulted in concern over the potential for increasing the risk of 
stroke and possibly malignancy-related death when haemoglobin targets of >13 mg/dL are 
aimed for. The optimum Hb target for kidney transplant recipients remains unknown. 
Future trials will need to assess these endpoints in the post-transplant situation in order to 
establish the safety of ESA in this setting. 
4.2 Iron therapy 
Replacement of depleted iron stores are necessary for the correction of PTA. Functional iron 
deficiency is a common problem in CKD populations and may also be a problem in kidney 
transplant recipients. The best form of iron replacement in this setting is yet to be 
established. Oral iron is poorly absorbed, often not tolerated, and may interfere with the 
absorption of immunosuppressants.  Intravenous iron has been used to replenish iron stores 
(Macdougall 1999) in transplant recipients as it has been in CKD patients in order to get 
around the problems of oral iron supplements. But a study currently in press but whose 
protocol was recently published (Mudge, Tan et al. 2009) showed that  intravenous versus 
oral iron was not associated with a reduction in PTA, but did lead to a non-significant 
reduction in gastro-intestinal side-effects, numerically fewer blood transfusions and was 
equally efficacious in the treatment of post-transplant anaemia. 
The measurement of iron status in post-kidney transplant patients, as in CKD patients, 
remains problematic. Existing measurements include serum iron, ferritin, and transferrin 
saturation. Ferritin is elevated in the setting of inflammation and therefore may not be 
indicative. New measures of iron status such as hepcidin show promise for more accurate 
estimation of iron status in this setting, but as yet a reference range has not been elucidated. 
4.3 Other treatments 
Other nutritional parameters such as B vitamins (B12, folate etc) are important in the 
pathogenesis of anaemia, and patients who have been treated with haemodialysis prior to 
transplantation are at risk of B-group vitamin deficiencies due to the removal of these water 
soluble vitamins with long-term dialysis, and especially with extended-hours dialysis 
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(Coveney, 2010). Most such patients would be supplemented with B-group vitamins during 
their dialysis treatment however. 
5. Conclusions 
PTA is a common problem in kidney transplant recipients and further studies are needed to 
better determine the relative contributions of iron deficiency, EPO deficiency, and bone 
marrow suppression, with a view to better determining the optimum strategy for its 
correction in individual patients. Anaemia is a risk factor for cardiovascular events and may 
be a contributor to the high cardiovascular event rate seen in kidney transplant recipients. 
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